Stock EDIT EDITAS MEDICINE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Editas Medicine, Inc.

Equities

EDIT

US28106W1036

Real-time Estimate Cboe BZX
Other stock markets
 01:56:19 2024-05-20 pm EDT 		5-day change 1st Jan Change
5.575 USD -0.80% Intraday chart for Editas Medicine, Inc. -2.63% -45.11%
May. 14 Editas Medicine Insider Bought Shares Worth $253,868, According to a Recent SEC Filing MT
May. 09 Barclays Adjusts Editas Medicine Price Target to $9 From $11, Maintains Equal Weight Rating MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Editas Medicine Insider Bought Shares Worth $253,868, According to a Recent SEC Filing
MT
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
GL
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
AQ
Editas Medicine Preclinical Data Highlights Advancement Of In Vivo Gene Editing Medicine Technologies at The American Society Of Gene And Cell Therapy Annual Meeting
AQ
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
GL
Barclays Adjusts Editas Medicine Price Target to $9 From $11, Maintains Equal Weight Rating
MT
Morgan Stanley Upgrades Editas Medicine to Equal-Weight From Underweight
MT
Transcript : Editas Medicine, Inc., Q1 2024 Earnings Call, May 08, 2024
Editas: Q1 Earnings Snapshot
AQ
Editas Medicine Announces First Quarter 2024 Results and Business Updates
GL
Editas Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
GL
Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration
MT
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
GL
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
CI
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
GL
Editas Medicine : April 2024 Corporate Presentation
PU
Editas Medicine : Corporate Effectiveness Report April 2024
PU
Transcript : Editas Medicine, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 02:05 PM
Barclays Adjusts Price Target on Editas Medicine to $11 From $10, Maintains Equal-Weight Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EDIT Stock
  4. News Editas Medicine, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW